Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4B | O94953 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476142 | 0.83 | MAPKAPK5 (0.48) | EGFRJAK3MAPKAPK5LMNATP53 | |
| SCHEMBL1674391 | 0.81 | WEE1 (0.41) | BTKEGFRLCKJAK3MAPKAPK5 | |
| SCHEMBL1475927 | 0.81 | MAPKAPK5 (0.61) | BTKEGFRLCKJAK3MAPKAPK5 | |
| SCHEMBL1475882 | 0.79 | MAPKAPK5 (0.37) | BTKMAPKAPK5TLR9TLR8TLR7 | |
| SCHEMBL4245164 | 0.78 | TLR9 (0.41) | TLR9TLR8TLR7 | |
| SCHEMBL1476412 | 0.76 | MAPKAPK5 (0.49) | BTKEGFRLCKJAK3MAPKAPK5 | |
| SCHEMBL1476537 | 0.76 | PIP4K2A (0.46) | BTKJAK3MAPKAPK5LMNATP53 | |
| SCHEMBL13910003 | 0.75 | MAPKAPK5 (0.52) | BTKEGFRLCKJAK3MAPKAPK5 | |
| SCHEMBL1475736 | 0.75 | MAPKAPK5 (0.66) | BTKEGFRLCKJAK3MAPKAPK5 | |
| SCHEMBL12748948 | 0.75 | MAPKAPK5 (0.52) | BTKEGFRLCKJAK3MAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | PTGES, IL1B, PTGER1 | BTK 4417/4885EGFR 4847/4885LCK 2250/4885 |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | P2RX5, P2RX3, IL1B | BTK 4104/4885EGFR 4837/4885LCK 2336/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | BTK 4104/4885EGFR 4837/4885LCK 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.